Beta cell imaging in type 1 diabetes with stable near-normal and unstable glucose control using PET - GLP1-reg

Radboud university medical center0 个研究点目标入组 18 人2017年7月24日

概览

暂无简介。

注册库

who.int

开始日期

2017年7月24日

结束日期

待定

最后更新

4年前

研究类型

Interventional clinical trial of medicinal product

性别

All

发起方

•lnclusion criteria: T1D patients with stable near\-normal glucose control:
•\- Age \=18 years
•\- T1D diagnosed \=1 year at the start of the study
•\- HbA1c \<7 (\<53 mmol/mol)
•\- 17\= BMI \=30 kg/m^2
•\- No severe hypoglycemic events in the past year and a maximum of 2 severe hypoglycemic events in their entire life.
•\- lntact hypoglycemic awareness as assessed by a score of 0 or 1 on the modified Clarke's questionnaire
•\- Ability to sign informed consent
•lnclusion criteria: T1D patients with unstable glucose control:
•\- Age \=18 years

•\- Previous treatment (within 6 months) with synthetic Exendin (Exenatide, Byetta®) or Dipeptidyl\-Peptidase lV
•\- Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of the normal range
•\- Renal disease defined as MDRD \<40 ml/min/1\.73 m^2
•\- Pregnancy or the wish to become pregnant within 6 months after the study
•\- Breastfeeding
•\- BMI \<17 kg/m^2 or BMI \>30 kg/m^2
•\- Age \<18 years
•\- lnability to sign informed consent